Vaderis is a clinical stage biotechnology company focussed on the treatment of rare and orphan diseases caused by Vascular Malformations.
Vaderis aims to be the first company in the world to develop a medicine for HHT. Vaderis is developing an oral medicine known as VAD044 which, if successful, will both treat the symptoms of HHT and will reduce the occurrence of new lesions, thereby modifying disease progression of HHT.
OUR PARTNERS
